Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Immudyne Pharmaceutical
Mt. Kisco, New York, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Immudyne's PureMune beta-glucan ingredient demonstrates rapid immune activation (3 hours), effective at a low dose (30 mg), activating multiple immune pathways (dectin-1, TLR, CR3); recent studies show increased immune markers (IFN-γ, IL-2) and reduced incidence/duration of respiratory symptoms in healthy adults
- Therapeutic areas
- Infectious DiseasesOtherDermatologyImmunology
- Modalities
- BiologicBeta-glucanNutraceutical ingredient
- Industry
- Non-Drug Biotech
02
Partnerships
AIDP, Inc. (functional ingredients, clinical research on PureMune)
Beyond the preview
Go deeper on Immudyne Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immudyne Pharmaceutical.